MedPath

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
Drug: Insulin glargine (HOE901)
Drug: Oral anti-diabetic drugs
Registration Number
NCT02752828
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 Diabetes.

Secondary Objective:

To compare the overall efficacy and safety of LixiLan to insulin glargine (with or without OADs) over a 26 Week treatment period in patients with type 2 Diabetes.

Detailed Description

The maximum study duration per patient will be approximately 29 weeks: an up to 2-week screening period, a 26-week randomized open-label treatment period and a 3-day post-treatment safety follow up period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
521
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LixiLanInsulin glargine/lixisenatide (HOE901/AVE0010)LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.
insulin glargineInsulin glargine (HOE901)Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.
LixiLanOral anti-diabetic drugsLixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.
insulin glargineOral anti-diabetic drugsInsulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted. Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period.
Primary Outcome Measures
NameTimeMethod
Change from baseline in HbA1cBaseline, 26 weeks
Secondary Outcome Measures
NameTimeMethod
Change from baseline in 7 point self monitored plasma glucose (SMPG) profiles during standardized meal testBaseline, 26 weeks
Percentage of patients reaching HbA1c <7% or ≤6.5%26 weeks
Change from baseline in body weightBaseline, 26 weeks
Percentage of patients reaching HbA1c <7% with no body weight gain and with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia26 weeks
Number of adverse events26 weeks
Change from baseline in 2-hour postprandial glucose (PPG) during standardized meal testBaseline, 26 weeks
Percentage of patients reaching HbA1c <7% at Week 26 with no documented (PG ≤70 mg/dL [3.9 mmol/L]) symptomatic hypoglycemia26 weeks
Percentage of patients requiring a rescue therapy26 weeks
Number of hypoglycemic events26 weeks
Measurement of anti-lixisenatide antibodies from baselineBaseline, 26 weeks
Measurement of anti-insulin antibodies from baselineBaseline, 26 weeks

Trial Locations

Locations (113)

Investigational Site Number 392024

🇯🇵

Chiba-Shi, Japan

Investigational Site Number 392025

🇯🇵

Atsugi-Shi, Japan

Investigational Site Number 392008

🇯🇵

Fujimi-Shi, Japan

Investigational Site Number 392048

🇯🇵

Hamamatsu-Shi, Japan

Investigational Site Number 392136

🇯🇵

Kamogawa-Shi, Japan

Investigational Site Number 392066

🇯🇵

Kashiwa-Shi, Japan

Investigational Site Number 392045

🇯🇵

Kashiwara-Shi, Japan

Investigational Site Number 392065

🇯🇵

Kawagoe-Shi, Japan

Investigational Site Number 392007

🇯🇵

Kawaguchi-Shi, Japan

Investigational Site Number 392077

🇯🇵

Kawasaki-Shi, Japan

Investigational Site Number 392119

🇯🇵

Kokubunji-Shi, Japan

Investigational Site Number 392086

🇯🇵

Kobe-Shi, Japan

Investigational Site Number 392001

🇯🇵

Koriyama-Shi, Japan

Investigational Site Number 392108

🇯🇵

Kumamoto-Shi, Japan

Investigational Site Number 392032

🇯🇵

Kurume-Shi, Japan

Investigational Site Number 392118

🇯🇵

Kushiro-Shi, Japan

Investigational Site Number 392122

🇯🇵

Minato-Ku, Japan

Investigational Site Number 392076

🇯🇵

Misato-Shi, Japan

Investigational Site Number 392042

🇯🇵

Mito-Shi, Japan

Investigational Site Number 392078

🇯🇵

Mito-Shi, Japan

Investigational Site Number 392026

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392148

🇯🇵

Nagano-Shi, Japan

Investigational Site Number 392131

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392134

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392127

🇯🇵

Niigata-Shi, Japan

Investigational Site Number 392144

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392117

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392040

🇯🇵

Oyama-Shi, Japan

Investigational Site Number 392095

🇯🇵

Onga-Gun, Japan

Investigational Site Number 392070

🇯🇵

Shimonoseki-Shi, Japan

Investigational Site Number 392021

🇯🇵

Shinjuku-Ku, Japan

Investigational Site Number 392081

🇯🇵

Shizuoka-Shi, Japan

Investigational Site Number 392027

🇯🇵

Suita-Shi, Japan

Investigational Site Number 392146

🇯🇵

Takamatsu-Shi, Japan

Investigational Site Number 392073

🇯🇵

Tsu-Shi, Japan

Investigational Site Number 392111

🇯🇵

Tomakomai-Shi, Japan

Investigational Site Number 392067

🇯🇵

Yatsushiro-Shi, Japan

Investigational Site Number 392012

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392039

🇯🇵

Yamato-Shi, Japan

Investigational Site Number 392126

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392055

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392147

🇯🇵

Fukuoka-Shi, Japan

Investigational Site Number 392100

🇯🇵

Gifu-Shi, Japan

Investigational Site Number 392079

🇯🇵

Hiki-Gun, Japan

Investigational Site Number 392022

🇯🇵

Ise-Shi, Japan

Investigational Site Number 392006

🇯🇵

Kasugai-Shi, Japan

Investigational Site Number 392062

🇯🇵

Kawaguchi-Shi, Japan

Investigational Site Number 392113

🇯🇵

Matsumoto-Shi, Japan

Investigational Site Number 392132

🇯🇵

Annaka-Shi, Japan

Investigational Site Number 392011

🇯🇵

Chigasaki-Shi, Japan

Investigational Site Number 392091

🇯🇵

Kawasaki-Shi, Japan

Investigational Site Number 392044

🇯🇵

Koga-Shi, Japan

Investigational Site Number 392088

🇯🇵

Maebashi-Shi, Japan

Investigational Site Number 392101

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392154

🇯🇵

Naka-Shi, Japan

Investigational Site Number 392084

🇯🇵

Saga-Shi, Japan

Investigational Site Number 392047

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392034

🇯🇵

Shimotsuke-Shi, Japan

Investigational Site Number 392013

🇯🇵

Chiyoda-Ku, Japan

Investigational Site Number 392109

🇯🇵

Hofu-Shi, Japan

Investigational Site Number 392139

🇯🇵

Kagoshima-Shi, Japan

Investigational Site Number 392002

🇯🇵

Adachi-Ku, Japan

Investigational Site Number 392052

🇯🇵

Chiyoda-Ku, Japan

Investigational Site Number 392155

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392143

🇯🇵

Fujisawa-Shi, Japan

Investigational Site Number 392054

🇯🇵

Fukuoka-Shi, Japan

Investigational Site Number 392059

🇯🇵

Hachioji-Shi, Japan

Investigational Site Number 392102

🇯🇵

Hamamatsu-Shi, Japan

Investigational Site Number 392009

🇯🇵

Arakawa-Ku, Japan

Investigational Site Number 392151

🇯🇵

Chiba-Shi, Japan

Investigational Site Number 392003

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392083

🇯🇵

Hakodate-Shi, Japan

Investigational Site Number 392112

🇯🇵

Hirosaki-Shi, Japan

Investigational Site Number 392053

🇯🇵

Kawagoe-Shi, Japan

Investigational Site Number 392114

🇯🇵

Kitamoto-Shi, Japan

Investigational Site Number 392089

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392004

🇯🇵

Sendai-Shi, Japan

Investigational Site Number 392103

🇯🇵

Sendai-Shi, Japan

Investigational Site Number 392098

🇯🇵

Shinjuku-Ku, Japan

Investigational Site Number 392037

🇯🇵

Shizuoka-Shi, Japan

Investigational Site Number 392057

🇯🇵

Iruma-Shi, Japan

Investigational Site Number 392129

🇯🇵

Kitakyushu-Shi, Japan

Investigational Site Number 392041

🇯🇵

Kitakyusyu-Shi, Japan

Investigational Site Number 392068

🇯🇵

Kitakyusyu-Shi, Japan

Investigational Site Number 392107

🇯🇵

Kyoto-Shi, Japan

Investigational Site Number 392082

🇯🇵

Kawasaki-Shi, Japan

Investigational Site Number 392142

🇯🇵

Kawasaki-Shi, Japan

Investigational Site Number 392028

🇯🇵

Kumamoto-Shi, Japan

Investigational Site Number 392092

🇯🇵

Kumamoto-Shi, Japan

Investigational Site Number 392075

🇯🇵

Kure-Shi, Japan

Investigational Site Number 392128

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392050

🇯🇵

Niihama-Shi, Japan

Investigational Site Number 392115

🇯🇵

Ogawa-Machi, Hikigun, Japan

Investigational Site Number 392071

🇯🇵

Okayama-Shi, Japan

Investigational Site Number 392051

🇯🇵

Takatsuki-Shi, Japan

Investigational Site Number 392069

🇯🇵

Saijo-Shi, Japan

Investigational Site Number 392150

🇯🇵

Sapporo-Shi, Japan

Investigational Site Number 392110

🇯🇵

Shinagawa-Ku, Japan

Investigational Site Number 392063

🇯🇵

Ube-Shi, Japan

Investigational Site Number 392030

🇯🇵

Saitama-Shi, Japan

Investigational Site Number 392074

🇯🇵

Sanda-Shi, Japan

Investigational Site Number 392097

🇯🇵

Sasebo-Shi, Japan

Investigational Site Number 392019

🇯🇵

Shobara-Shi, Japan

Investigational Site Number 392018

🇯🇵

Shunan-Shi, Japan

Investigational Site Number 392056

🇯🇵

Taito-Ku, Japan

Investigational Site Number 392061

🇯🇵

Tokorozawa-Shi, Japan

Investigational Site Number 392035

🇯🇵

Zentsuji-Shi, Japan

Investigational Site Number 392094

🇯🇵

Fukuoka-Shi, Japan

Investigational Site Number 392017

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392020

🇯🇵

Izumisano-Shi, Japan

Investigational Site Number 392133

🇯🇵

Kitaazumi-Gun, Japan

Investigational Site Number 392093

🇯🇵

Ube-Shi, Japan

Investigational Site Number 392029

🇯🇵

Toyonaka-Shi, Japan

© Copyright 2025. All Rights Reserved by MedPath